Pages that link to "Q45873192"

The following pages link to Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. (Q45873192):

Displaying 28 items.

• Future of coagulation factor replacement therapy (Q26820824) (← links)
• Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future (Q26853631) (← links)
• Liposomes as nanomedical devices (Q28088315) (← links)
• Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. (Q36912731) (← links)
• Successful treatment of canine hemophilia by continuous expression of canine FVIIa (Q37162830) (← links)
• Recombinant factor VIII in the management of hemophilia A: current use and future promise (Q37230340) (← links)
• Molecular approaches for improved clotting factors for hemophilia (Q37334700) (← links)
• Delivery of therapeutic proteins (Q37668486) (← links)
• Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue (Q37670958) (← links)
• Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. (Q37679949) (← links)
• Visions in haemophilia care (Q37683086) (← links)
• Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. (Q37686530) (← links)
• Special lectures in haemophilia management. (Q37768867) (← links)
• The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. (Q37790614) (← links)
• Hemophilia: New Protein Therapeutics (Q37829216) (← links)
• Current Options and New Developments in the Treatment of Haemophilia (Q37841547) (← links)
• Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia (Q37859903) (← links)
• Nanocarrier possibilities for functional targeting of bioactive peptides and proteins:state-of-the-art (Q37948968) (← links)
• The hope and reality of long-acting hemophilia products (Q37990479) (← links)
• Investigational drugs for coagulation disorders (Q38106245) (← links)
• Role of enhanced half-life factor VIII and IX in the treatment of haemophilia (Q38371071) (← links)
• The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. (Q39475869) (← links)
• Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. (Q41975229) (← links)
• Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs (Q42220577) (← links)
• Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study. (Q45859289) (← links)
• Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients. (Q45878435) (← links)
• Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model. (Q45887979) (← links)
• Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review (Q91788893) (← links)